Founded in 2015, APRINOIA is developing novel therapeutics and precision diagnostics for neurodegenerative diseases in collaboration with leading global biotech companies such as Biogen and Celgene. The company was planning to go public with a SPAC merger, but the IPO was withdrawn in October 2024, maintaining its private status as it advances its clinical pipeline.
Cyborg Score Rationale
APRINOIA has a focused pipeline in high-value neurodegenerative disease space with FDA progress on its lead diagnostic asset (APN-1607) and strategic pharma partnerships. However, the failed public listing and early-stage therapeutic programs create execution risk.
Top Insights
Lead candidate APNmAb005 is a humanized anti-tau antibody targeting tau aggregates in tau-related diseases including Alzheimer's
FDA granted "Study May Proceed" letter for Phase 3 study of APN-1607 for diagnosis of Progressive Supranuclear Palsy
Protein degrader programs for tau and alpha-synuclein are at lead optimization stages aiming for improved properties and oral dosing
China rights of APN-1607 are licensed to large pharmaceutical company with 2024 commercialization target